The discovery of an ideal, and effective autoimmune inhibitor is urgently required. The available therapies have substantial side effects, susceptibility to infections, metabolic disturbances, and organ toxicity. The solute carrier family 15 member 4 is a proton- coupled oligopeptide transporter that is mainly expressed in immune cells, according to several evidence sources. It has emerged as a viable target for investigating new regimens. The diverse pharmacological activities of amino-pyrazole-containing nuclei have made them noteworthy in the realm of medicinal chemistry. This study’s primary goal is to investigate the effects of nuclei containing aminopyrazoles on the SLC15A4 protein. Receptor-based pharmacophore modeling was created and tested using the carefully selected amino-pyrazole libraries to test our hypothesis. The best aligned pharmacophoric featured hits were assessed for binding affinities and molecular interactions. Taking standard control as co-crystal of SLC15A4, three promising hits PubChem CID 17558339, 16191329, and 16188575 were confirmed based on their binding affinities, molecular interactions, molecular dynamics, and optimal ADMET profiles. Our findings represent a promising starting point for developing multi-modal regimens that act alleviate autoimmune disease syndromes.